<DOC>
	<DOCNO>NCT01381458</DOCNO>
	<brief_summary>This retrospective database study ass difference risk re-hospitalization COPD-related exacerbation cost patient receive fluticasone propionate/salmeterol xinafoate combination 250/50 ( FSC ) versus anticholinergic [ i.e . tiotropium ( TIO ) ipratropium combination ipratropium-albuterol ( collectively refer ipratropium - IPR ) ] post-hospitalization Emergency Department ( ED ) visit treatment COPD . This hypotheses test study . Associations compare FSC AC cohort . Hypotheses primary outcome key secondary outcome present : Specifically study hypothesis primary outcome test : Ho : There difference risk COPD-related hospitalization FSC AC Ha : There difference risk COPD-related hospitalization FSC AC Hypothesis key secondary outcome COPD-related cost test : Ho : There difference COPD-related cost FSC AC Ha : There difference COPD-related cost FSC AC</brief_summary>
	<brief_title>Risk Re-Hospitalization Patients With Chronic Obstructive Pulmonary Disease ( COPD ) Post Exacerbation</brief_title>
	<detailed_description>Managed care patient ( age &gt; 40 year ) fluticasone propionate/salmeterol xinafoate combination ( FSC ) -naive 12 month pre-index period . The index-date date discharge index Chronic Obstructive Pulmonary Disease ( COPD ) -related hospitalization/Emergency Department ( ED ) visit . Eligible patient require newly initiate switch drug therapy FSC ipratropium ( IPR ) / tiotropium ( TIO ) identification period ( 01/01/2004 01/31/2008 ) treat COPD . Patients switch another maintenance medication exacerbation treatment assessment period ( 30-days post-index date ) exclude study . Follow-up period 12 month post treatment assessment period . Patients classify FSC 250/50 versus anticholinergic ( TIO , IP IPR ) . Examined risk COPD-related exacerbation hospitalization , emergency department ( ED ) visit , COPD-related physician/outpatient visit oral corticosteroid ( OCS ) antibiotic prescription ( ABX ) within 5 day physician/outpatient visit COPD-related medical , pharmacy , total healthcare cost follow-up period .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>â‰¥40 year age index discharge date Continuous health plan eligibility preindex , treatment assessment , followup period Absence fluticasone propionate salmeterol xinafoate dos combination product budesonideformoterol anytime preindex , treatment assessment , followup period COPDrelated exacerbation treatment assessment period Any therapy change , define switch augment index therapy treatment assessment period Absence comorbid condition ( respiratory cancer , cystic fibrosis , fibrosis due tuberculosis , bronchiectasis , pneumonociosis , pulmonary fibrosis , pulmonary tuberculosis , sarcoidosis ) preindex , treatment assessment , followup period</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>